Publicaciones
El conocimiento generado en IrsiCaixa se comparte con la comunidad científica a través de la publicación de artículos en revistas científicas de alto impacto.
Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19.
Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome.
Gut microbiome signatures linked to HIV-1 reservoir size and viremia control.
Preserved central nervous system functioning after use of romidepsin as a latency-reversing agent in an HIV cure strategy.
Considerations for successful therapeutic immunization in HIV cure.
Incoming HIV virion-derivedGag Spacer Peptide 2 (p1) is a targetof effective CD8+T cell antiviral responses
Absence of drug-drug interactions between γ-hydroxybutyric acid (GHB) and cobicistat.
Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection.
HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).
Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent.